Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 7, 2015, Pages 1299-1307

  Solomon, Scott R ^a   Sizemore, Connie A ^a   Sanacore, Melissa ^a   Zhang, Xu ^b   Brown, Stacey ^a   Holland, H Kent ^a   Morris, Lawrence E ^a   Bashey, Asad ^a  

^a NORTHSIDE HOSPITAL   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

Author keywords

Haploidentical; Myeloablative; Peripheral blood stem cells; Stem cell transplantation; Total body irradiation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; METHOTREXATE; MYCOPHENOLATE MOFETIL; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYELOABLATIVE AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; BACTEREMIA; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYSTITIS; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RADIATION DOSE; SIBLING; STEM CELL TRANSPLANTATION; THROMBOCYTE; WHOLE BODY RADIATION; ACUTE DISEASE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHRONIC DISEASE; CLINICAL TRIAL; GRAFT VS HOST DISEASE; HAPLOTYPE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; ISOGRAFT; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; RISK; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; UNRELATED DONORS;

ACUTE DISEASE; ADULT; CHRONIC DISEASE; CYCLOPHOSPHAMIDE; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; RECURRENCE; RISK; SURVIVAL ANALYSIS; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, ISOGENEIC; UNRELATED DONORS; WHOLE-BODY IRRADIATION;

EID: 84930574820     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.03.003     Document Type: Article

References (45)

1. Gragert L., Eapen M., Williams E., et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. NEngl J Med 2014, 371:339-348.
2. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. NEngl J Med 1985, 313:765-771.
3. Szydlo R., Goldman J.M., Klein J.P., et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. JClin Oncol 1997, 15:1767-1777.
4. Aversa F., Terenzi A., Tabilio A., et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. JClin Oncol 2005, 23:3447-3454.
5. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
6. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
7. Grosso D., Carabasi M., Filicko-O'Hara J., et al. A2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood 2011, 118:4732-4739.
8. Raiola A.M., Dominietto A., Ghiso A., et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013, 19:117-122.
9. Solomon S.R., Sizemore C.A., Sanacore M., et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012, 18:1859-1866.
10. Zaucha J.M., Gooley T., Bensinger W.I., et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001, 98:3221-3227.
11. Mohty M., Bilger K., Jourdan E., et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003, 17:869-875.
12. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
13. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2005, 11:945-956.
14. Armand P., Kim H.T., Logan B.R., et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014, 123:3664-3671.
15. O'Donnell P.V., Luznik L., Jones R.J., et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002, 8:377-386.
16. Aoudjhane M., Labopin M., Gorin N.C., et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005, 19:2304-2312.
17. Mohty M., Labopin M., Volin L., et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010, 116:4439-4443.
18. Ringdén O., Labopin M., Ehninger G., et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. JClin Oncol 2009, 27:4570-4577.
19. Shimoni A., Hardan I., Shem-Tov N., et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006, 20:322-328.
20. Zhang H., Chen J., Que W. Allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. Leuk Res 2012, 36:431-437.
21. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. JClin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
22. Chang Y.J., Weng C.L., Sun L.X., Zhao Y.T. Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials. Ann Hematol 2012, 91:427-437.
23. Nagler A., Rocha V., Labopin M., et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen-a report from the acute leukemia working party of the European group for blood and marrow transplantation. JClin Oncol 2013, 31:3549-3556.
24. Copelan E.A., Hamilton B.K., Avalos B., et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood 2013, 122:3863-3870.
25. Ringden O., Remberger M., Ruutu T., et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999, 93:2196-2201.
26. Litzow M.R., Perez W.S., Klein J.P., et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 2002, 119:1115-1124.
27. Grosso D., Gaballa S., Alpdogan O., et al. Atwo-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease. Biol Blood Marrow Transplant 2015, 21:646-652.
28. Symons H.J., Chen A., Gamper C., et al. Haploidentical BMT using fully myeloablative conditioning, T cell replete bone marrow grafts, and post-transplant cyclophosphamide (PT/Cy) has limited toxicity and promising efficacy in largest reported experience with high risk hematologic malignancies. Biol Blood Marrow Transplant 2015, 21:S29.
29. Kastan M., Schlaffer E., Russo J., et al. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990, 75:1947-1950.
30. Yaghobi R., Ramzi M., Dehghani S. The role of different risk factors in clinical presentation of hemorrhagic cystitis in hematopoietic stem cell transplant recipients. Transplant Proc 2009, 41:2900-2902.
31. Trotman J., Nivison-Smith I., Dodds A. Haemorrhagic cystitis: incidence and risk factors in a transplant population using hyperhydration. Bone Marrow Transplant 1999, 23:797-801.
32. Silva Lde P., Patah P.A., Saliba R.M., et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica 2010, 95:1183-1190.
33. Seber A., Shu X.O., Defor T., et al. Risk factors for severe hemorrhagic cystitis following BMT. Bone Marrow Transplant 1999, 23:35-40.
34. Ogawa H., Ikegame K., Yoshihara S., et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006, 12:1073-1084.
35. Lu D.P., Dong L., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006, 107:3065-3073.
36. Kroger N., Zabelina T., Kruger W., et al. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant 2001, 27:349-354.
37. Tiercy J.M. Unrelated hematopoietic stem cell donor matching probability and search algorithm. Bone Marrow Res 2012, 2012:695018.
38. Rambaldi A., Bacigalupo A., Fanin R., et al. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. Leukemia 2012, 26:1779-1785.
39. Heemskerk M.B., van Walraven S.M., Cornelissen J.J., et al. How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more!. Bone Marrow Transplant 2005, 35:645-652.
40. van Agthoven M., Groot M.T., Verdonck L.F., et al. Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia. Bone Marrow Transplant 2002, 30:243-251.
41. Frassoni F., Labopin M., Powles R., et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 2000, 355:1393-1398.
42. Craddock C., Labopin M., Pillai S., et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia. Leukemia 2011, 25:808-813.
43. Saito A.M., Cutler C., Zahrieh D., et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant 2008, 14:197-207.
44. Khera N., Zeliadt S.B., Lee S.J. Economics of hematopoietic cell transplantation. Blood 2012, 120:1545-1551.
45. Matthes-Martin S., Potschger U., Barr R., et al. Costs and cost-effectiveness of allogeneic stem cell transplantation in children are predictable. Biol Blood Marrow Transplant 2012, 18:1533-1539.